SKB264 plus QL1706 for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have recurrent or metastatic cervical cancer (squamous cell, adenocarcinoma, or adenosquamous types) that cannot be treated with surgery or radiation.
- You have already tried at least one platinum-based chemotherapy and it either stopped working, caused too many side effects, or your cancer came back within 6 months of finishing it.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are generally active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) for cervical cancer that has stopped responding to earlier PD-1 therapies. The goal is to see if this drug can help shrink tumors or slow down the cancer.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This study tests a new combination of drugs for women with advanced cervical cancer that has not been previously treated. The goal is to see if the combination can shrink tumors or slow down the cancer, and to check its safety.
This trial tests giving a combination of an immunotherapy drug (QL1706) and two chemotherapy drugs (cisplatin and paclitaxel) before surgery for cervical cancer. The goal is to shrink the tumor to make surgery more effective and improve outcomes.
This trial tests a new drug (QL1706) combined with chemotherapy before the usual radiation therapy for locally advanced cervical cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.